# Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

> **NCT04625595** · PHASE1 · COMPLETED · sponsor: **Immunomolecular Therapeutics, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Type1 Diabetes

## Interventions

- **DRUG:** 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
- **DRUG:** 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
- **DRUG:** 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
- **DRUG:** 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule

## Key facts

- **NCT ID:** NCT04625595
- **Lead sponsor:** Immunomolecular Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-09
- **Primary completion:** 2021-05-11
- **Final completion:** 2021-07-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625595, "Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04625595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*